In the BioHarmony Drug Report Database

"Preview" Icon

Letermovir

Prevymis (letermovir) is a small molecule pharmaceutical. Letermovir was first approved as Prevymis on 2017-11-08. It has been approved in Europe to treat cytomegalovirus infections. Prevymis’s patents are valid until 2033-02-28 (FDA).

 

Trade Name

 

Prevymis
 

Common Name

 

letermovir
 

ChEMBL ID

 

CHEMBL1241951
 

Indication

 

cytomegalovirus infections
 

Drug Class

 

Antivirals

Image (chem structure or protein)

Letermovir structure rendering